The U.S. contraceptive market size was valued at around USD 8.3 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of around 5.16% from 2023 to 2030. Increase in the use of modern contraceptives and rise in awareness among adolescents and the young population about sexual health and family planning are key factors that driving the U.S. market growth. Moreover, government programs have led to an increase in access to contraceptives that help prevent unwanted pregnancies in teenagers.
Development, approval, and commercialization of new, more effective, and long-acting reversible contraceptive methods are expected to drive the industry scale during the forecast period. For instance, Agile Therapeutics developed a hormonal patch, Twirla, which was introduced in the U.S. in the fourth quarter of 2020. The launch of generic and low-cost drugs and devices has led to an increase in the demand for contraceptives by teenagers as well. Furthermore, the demand for nonhormonal contraceptives in the U.S. is increasing since they eliminate the risk of adverse effects associated with hormonal imbalance in the body.
Improving access to Family Planning and Reproductive Health (FP/RH) services can have a positive impact on the economy as the number of unintended pregnancies and maternal deaths would be limited. The U.S. government supports global FP/RH efforts which is one of the largest distributors and purchasers of contraceptives.
In 29 U.S. states, insurers are required to provide a full range of coverage for FDA-approved contraceptive methods for women. In 12 states, over-the-counter contraceptives are covered; however, insurers may require a prescription from the beneficiary. In 20 states and the District of Columbia, insurers are required to cover an extended supply of contraceptives at one time.
Post COVID Outlook
Visits and consultation for physician-administered contraceptives such as injectables, rings, and IUDs witnessed slow growth as healthcare providers were re-scheduling appointments to avoid frequent visits to physicians’ offices.
An increase in vaccination and reduced burden of COVID-19 patients helped restore the physician office visits for contraceptive administration, in turn contributing to product demand.
Contraceptive manufacturers, such as Merck & Co., reported a reduction indemand for contraceptive implant, Nexplanon, due to the prioritization of COVID-19 patients by healthcare providers.
Demand for long-acting and nonhormonal contraceptives is expected to increase in the coming years due to convenience, long-term protection, and fewer side effects demonstrated by these contraceptives.
The COVID-19 pandemic has significantly impacted the U.S. healthcare sector. The contraceptives market is majorly dependent on physician-prescribed and physician-administered products. Due to restrictions on visiting physician offices without an emergency the demand for contraceptive products was low during the first few months of the pandemic. Telehealth services and virtual consultations were recommended for contraceptive screening and counseling.
Furthermore, demand for nonhormonal contraceptives in young women is expected to increase as they want to avoid risks associated with hormonal contraceptives. Newly developed products, such as nonhormonal vaginal rings, diaphragms, and innovative condoms, are expected to aid the growth of the nonhormonal products segment during the forecast period.
The U.S. contraceptive market has been segmented into pills, Intrauterine Devices (IUD), condoms, vaginal ring, subdermal implant, injectable, and others. Subdermal implants segment is expected to witness the highest growth with a CAGR of 9.62% over the forecast period. In 2022, Oral contraceptives pills accounted for the largest market share of 37.44% due to large number of products introduced by several market players, a high success rate (99.0% when used perfectly), and convenience in using oral pills for contraception. These medicines are available only via a gynecologist’s prescription and can be used for other conditions as well, such as dysmenorrhea, amenorrhea, hypermenorrhea, endometriosis, and others. The popularity of pills among young women in the U.S. can be attributed to safety and ease of administration.
The popularity of male condoms is high among young individuals due to easy availability, economic pricing, and added advantage of protection against STDs. Moreover, the availability of a vast range of variants in various sizes, flavors, textures, and thickness helps enhance sexual experience of users. In April 2017, Church & Dwight Co., Inc. launched a new range of condoms, XOXO that were available in gender-neutral colors. The product is designed to appeal to women and provide enhanced sexual experience.
Furthermore, the acceptance of long-acting reversible contraceptives has significantly improved in the last decade. Intrauterine devices, injectables, and vaginal rings are expected to witness sustainable growth during the forecast period. The market is driven by cost-effectiveness and longer duration of product life. The launch of new products and ease of use of vaginal rings are factors expected to increase demand for such methods of birth control. TherapeuticsMD Inc.’s Annovera—a reusable silicone ring that provides protection for up to 1 year from unintended pregnancy gained FDA approval & market exclusivity of 5 years as a new chemical entity in September 2018 and was be launched commercially in the first quarter of 2020.
The regional market is highly competitive due to the presence of several companies. Most of the companies are undertaking strategic initiatives, such as investments in R&D for developing innovative products and to gain a competitive edge over others. In February 2020, Afaxys, Inc. and TherapeuticsMD, Inc. signed an agreement to increase access to Annovera in the U.S. public healthcare system. In July 2020, TherapeuticsMD, Inc. entered into an agreement with Nurx—an online company for women’s health-for increasing its access to Annovera. High investments by prominent companies for the commercialization of effective and long-term reversible contraceptives have increased the awareness levels about these products. Some of the prominent companies in the U.S. contraceptive market include:
Church & Dwight Co., Inc.
Reckitt Benckiser Group Plc
Organon Group Of Companies
Teva Pharmaceutical Industries Ltd.
The Cooper Companies, Inc.
Mayer Laboratories, Inc.
The market size value in 2023
USD 8.7 billion
The revenue forecast in 2030
USD 12.4 billion
CAGR of 5.16% from 2023 to 2030
The base year for estimation
2017 - 2021
2023 - 2030
Revenue in USD billion and CAGR from 2023 to 2030
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Key companies profiled
Church & Dwight Co. Inc.; Reckitt Benckiser Group Plc; Veru, Inc.; Organon Group Of Companies; Pfizer, Inc.; Teva Pharmaceutical Industries Ltd.; The Cooper Companies, Inc.; Mayer Laboratories, Inc.; Agile Therapeutics; TherapeuticsmMD, Inc.; Bayer Ag; Afaxys, Inc.; Mithra Pharmaceuticals; Abbvie
Free report customization (equivalent to up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Grand View Research has segmented the U.S. contraceptive market based on product:
Product Outlook (Revenue, USD Billion, 2017 - 2030)
Intrauterine Devices (IUD)
b. The U.S. contraceptive market size was estimated at USD 8.3 billion in 2022 and is expected to reach USD 8.7 billion in 2023.
b. The U.S. contraceptive market is expected to grow at a compound annual growth rate of 5.16% from 2023 to 2030 to reach USD 12.4 billion by 2030.
b. Pills dominated the U.S. contraceptive market with a share of around 37.4% in 2022. This is attributable to a large number of products introduced by several market players, a high success rate, and the convenience of using oral pills for contraception.
b. Some key players operating in the U.S. contraceptive market include Merck & Co. Inc.; Bayer AG; Allergan; Afaxys, Inc.; Mayer Laboratories, Inc.; Teva Pharmaceutical Industries Ltd.; Agile Therapeutics; TherapeuticsMD Inc.; Reckitt Benckiser Plc.; Pfizer, Inc.; Cooper Surgical; Church & Dwight Co., Inc.; and Mithra Pharmaceuticals.
b. Key factors that are driving the U.S. contraceptive market growth include increasing awareness regarding the importance of sexual and reproductive health among women in the age group of 15 to 49 years.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
"The quality of research they have done for us has been excellent."